key: cord-0870034-ggo83xy3
authors: Barssoum, Kirolos; Victor, Varun; Salem, Ahmad; Kumar, Ashish; Mubasher, Mahmood; Hassib, Mohab; Magdi, Mohamed; Renjithlal, Sarathlal; Abdelazeem, Mohamed; Shariff, Mariam; Idemudia, Osarenren; Ibrahim, Mounir; Mohamed, Amr; Thakkar, Samarthkumar; Patel, Harsh; Diab, Mohamed; Szeles, Andras; Ibrahim, Fadi; Jha, Roshan; Chowdhury, Medhat; Akula, Navya; Kalra, Ankur; Nanda, Navin C.
title: Echocardiography, lung ultrasound, and cardiac magnetic resonance findings in COVID‐19: A systematic review
date: 2021-07-08
journal: Echocardiography
DOI: 10.1111/echo.15152
sha: f93dbe486e014db56f4e0cf8720d6b4fa7e2bd9a
doc_id: 870034
cord_uid: ggo83xy3

BACKGROUND: The manifestations of COVID‐19 as outlined by imaging modalities such as echocardiography, lung ultrasound (LUS), and cardiac magnetic resonance (CMR) imaging are not fully described. METHODS: We conducted a systematic review of the current literature and included studies that described cardiovascular manifestations of COVID‐19 using echocardiography, CMR, and pulmonary manifestations using LUS. We queried PubMed, EMBASE, and Web of Science for relevant articles. Original studies and case series were included. RESULTS: This review describes the most common abnormalities encountered on echocardiography, LUS, and CMR in patients infected with COVID‐19.

We performed a systematic search of the PubMed, EMBASE, and Web of science databases to identify relevant articles from the inception of the database to October 2, 2020. The search strategy used in each database is elaborated in Table S1 . Extracted citations were imported into Mendeley reference manager and screened for relevance. Screening was performed at two levels. At the first level, articles and abstracts were screened for relevance. At the second level, articles identified by title and abstract screening were subjected to full text review. A second manual search was performed to identify articles published after the initial search until publication. The PRISMA flow chart for inclusion of studies is described in Figure 1 .

2.1.1 Indications for echocardiography in COVID- 19 patients The American Society of Echocardiography (ASE) and other clinical societies have established appropriate criteria for the use of echocardiography (ECHO) in patients admitted to the hospital. 2 Given the increasing evidence for cardiovascular manifestations of COVID- 19 , and the increasing role of bedside focused cardiac ultrasound (FoCUS) in clinical management, performing a focused bedside ECHO among patients with COVID-19 can prove beneficial, especially in the F I G U R E 1 PRISMA flow chart for study inclusion critically ill. [3] [4] [5] Although, performing an ECHO solely based on troponin elevation is not recommended, there is an increasing body of data suggesting that elevated troponin (> 99th percentile on admission) is an important predictor of mortality and length of hospital stay in patients with COVID-19. [6] [7] [8] [9] [10] Similarly, NT-ProBNP has also been found to be elevated among a significant number of patients with COVID-19 and is an important predictor of mortality. 11 One study demonstrated that among patients with COVID-19, echocardiogram changed the management in 33% of patients who exhibited a variety of symptoms and signs including chest pain, electrocardiogram (EKG) changes, and elevated cardiac biomarkers. 12 Despite studies demonstrating that health care workers have a significantly higher risk of acquiring COVID-19 due to increased workplace exposure to patients, 14 the data regarding the incidence of COVID-19 among ECHO sonographers is scarce.

In a recent cross-sectional study that surveyed sonographers in major academic centers in New York (NY, USA), it was found that there was an infrequent use of plastic ECHO machine covers (9%), barriers between the patient and sonographer (11%), and probe covers (30%) during the procedures. In addition, about a quarter of respondents reported a lack of training in disinfection practices of ultrasound equipment. 15 Such findings highlight the need for more stringent adherence to the ASE and American Institute of Ultrasound in Medicine's guidelines for protection of patients and ECHO providers to safeguard this vulnerable population. 16 

Transthoracic echo (TTE) in prone patients with It was found that raising the patient's left arm and placing a pillow or a folded sheet underneath the mid-thoracic wall to maintain the left hemithorax slightly elevated to allow a comfortable transducer manipulation, resulted in successful apical four and five chamber views and related measurements. 17 Alternatively, the lower thoracic section of the patient's air mattress can be temporarily deflated, taking advantage of the gravitational effect of the heart and its shift towards the chest wall while obtaining an apical four chamber view. These views were adequate to estimate the left ventricular ejection fraction (LVEF), mitral annular plane systolic excursion, mitral valve, and annular doppler velocities, aortic valve doppler velocity, tricuspid annular plane systolic excursion (TAPSE), and pulmonary arterial systolic pressure (PASP). 18 

Contrast echocardiography in patients undergoing extra-corporeal membrane oxygenation (ECMO) Though , the use of ultrasound enhancement agents (UEAs) during TTE have been evaluated in COVID-19 patients who were spontaneously breathing or on mechanical ventilation, [19] [20] [21] their use during TTE in the setting of extracorporeal membrane oxygenation (ECMO) for COVID-19 acute respiratory distress syndrome (ARDS) can be potentially problematic. UAE can trigger an air bubble alarm, which is integrated in ECMO circuits as a safety measure. This can result in stoppage of the ECMO circuit forward flow or engaging a "Zero-flow mode" which can result in rapid deterioration of hypoxic patients who are dependent on ECMO flow. 22 Bleakley et al. used a protocol that involves the deactivation of air-bubble alarms before administration of contrast to avoid such potential complication. 22 

Transesophageal echo (TEE) in COVID-19: A new outlook TEE offers multiple advantages, including better imaging windows by virtue of the TEE probe being close to the cardiac chambers and great vessels compared with conventional TTE probes. In addition, TEE is not hampered by other factors such as high positive end-expiratory pressure (PEEP) ventilation, prone position, body habitus, and emphysematous lungs, that constitute a limiting factor for obtaining good images by TTE. 23, 24 Studies demonstrated that superior vena caval (SVC) collapsibility index (which requires TEE) was superior to inferior vena cava (IVC) distensibility index (measured using TTE) in predicting fluid responsiveness. 25, 26 Also, TEE can be used to better evaluate the right ventricular (RV) fractional area change (FAC) 27 and tricuspid longitudinal annular displacement (TMAD) 28, 29 which are surrogates of RV dysfunction.

TTE and TEE can play a role in identifying patients who will benefit from veno-venous ECMO versus veno-arterial ECMO. Also, they can be useful tools for assisting in cannulations and troubleshooting the device. [30] [31] [32] [33] For instance, embryologic remnants of right heart structures or other congenital abnormalities may affect the safe and appropriate placement of venous cannulas during ECMO initiation.

A persistent left SVC leading to a dilated coronary sinus may be accidentally cannulated, leading to compromised oxygenation on ECMO.

Similarly, a prominent Chiari network may impede cannula positioning and may increase the risk of subsequent thrombosis. TEE guidance can help in confirming the course of a guidewire during insertion and help in excluding coiling of the guidewire in the right atrium, crossing of the guidewire across the interatrial septum or its entrance in the coronary sinus. It can also ensure that, the return cannula is positioned clear of the interatrial septum and the tricuspid valve, thereby, reducing the risk for re-cannulation. 33 

Doppler indicators of DD were frequently reported in COVID-19

patients. However, their findings were heterogenous among studies.

But DD seems to be more common than systolic dysfunction in patients with COVID-19(16% vs 10%). 46 As mentioned earlier, elevated PASP has found to be associated with a higher in-hospital mortality. 38 Studies have consistently shown RV dysfunction to be a predictor of disease severity. Mortality rate has found to be increased in patients with moderate/severe dilation of the RV as compared with patients with mild/no RV dilation. 49 One study reported that RV dilatation correlates with high sensitivity troponins, and d-Dimer levels. 55, 79, 80 Of note, decreased RVGLS and RVFWS have been found to predict mortality independent of respiratory parameters, LV function or markers of multi-organ failure. 47, 79, 81 In addition, oxygen need, higher d-Dimer and C-reactive protein (CRP) correlated with lower RVGLS. 47, 79, 81 In a study of 49 COVID-19 patients with the majority on oxygen or non-invasive ventilation, both RVFWS and RVGLS were significantly decreased in non-survivors compared with survivors, with both having the highest area under curve (AUC) for predicting mortality as compared with other parameters. 47 In another study, where seven patients were discharged and five needed intubation or died, both RVGLS and RVFWS were significantly lower in patients with poor outcomes compared with those with favorable outcomes. 82 Also, lower RVFWS was an independent predictor of mortality in 100 COVID-19 patients with 44 patients classified as severe disease. 55 A cut-off of -23% was found to have a sensitivity of 94% for predicting mortality among COVID-19 patients in one study. 79 In another study of 35 patients, those with RVGLS less than -20% had significantly higher 30 day mortality. 83 RVFAC performed inconsistently in prediction of mortality in COVID-19 patients. In one study that included COVID-19 patients with varying severity, RVFAC was reported to be an independent predictor of mortality. 71 In another study of 128 COVID-19 patients with more than 50% of patients considered critical, low RVFAC, RV strain pattern, and 3D RV ejection fraction (EF) were independent predictors of mortality in their respective order with low 3D RVEF having the highest predictive value. 70 However, in other studies among COVID-19 patients RVFAC was not significantly different between survivors compared with non-survivors. 47, 55, 56 Finally, a study by D'Alto et al. demonstrated that right ventriculararterial uncoupling expressed as TAPSE/PASP is an independent predictor of mortality in COVID-19 patients. 29 With regards to LV parameters, mortality was found to be increased in patients who had reduced LV longitudinal strain (LS), left ventricular stroke volume index (LVSVi), cardiac index and tissue Doppler S' (systolic wave) velocity. 80 In addition, Giustino et al. demonstrated that the mortality rate in COVID-19 patients with myocardial injury, defined as elevated cardiac biomarkers, was higher in patients with evidence of WMAs as compared with those without WMAs. 64 Moreover, decreased LVGLS was found to be a strong predictor of mortality or poor outcomes. 44 RV FWS is a more sensitive parameters for RV dysfunction, and correlates more consistently with worse outcomes than conventional ECHO parameters.

On the other hand, compared with RV dysfunction, LV dysfunction is less frequent presentation in patients with COVID-19, in fact DD is relatively frequently compared with systolic dysfucntion. However DD, does not correlate with worse outcomes. LV WMA in the mid, apex, and base are frequently reported due to myocarditis, stress cardiomyopathy or true ischemic events and are more frequently seen in patients with myocardial injury with EKG changes. Moreover, LVGLS is impaired frequently in patients with COVID-19 irrespective of systolic or diastolic dysfunction and is more affected in patients with severe disease with positive cardiac biomarkers and is an independent predictor of mortality.

Echocardiographic follow up is warranted in patients with newly impaired RV or LV dysfunction and/or WMA. These abnormalities seem to be transient and even subclinical involvement as evidenced by LVGLS and/or RVFWS resolves on follow up echo with no intervention.

The most commonly used protocol for performing lung ultrasound investigation. This also includes the BLUE "bed-side lung ultrasound in emergency" protocol for LUS, which acquires images in a similar scanning fashion. 87 The most commonly used transducers were convex (Curvilinear) probes, however, phased array and linear transducers were also used.

The most common LUS findings in screened studies and their relative prevalence were irregular pleural lines (27.9-89% in patients), pleural thickening (6.5-86%), separate "distinct or scattered" B-lines and peripheral pulmonary zones distribution of LUS findings. 92 Interestingly, a more prominent involvement of the anterior areas of the lungs was noted in patients with severe disease relative to those with mild disease (36% vs 21% of patients, p .021), 99 and clinical deterioration was associated with loss of aeriation in anterior lung segments. 100 Higher prevalence of bilateral involvement and anterior areas involvement in severe disease seems to be a recurring finding among the reviewed studies. 

A chest computed tomography (CT) scan is considered as the gold standard for the diagnosis of COVID-19 pneumonia, having a sensitivity greater than RT-PCR. 105 Zieleskiewicz L et al. demonstrated a significant association between LUS score and chest CT severity.

A LUS score > 23 predicted severe SARS-CoV-2 pneumonia (specificity > 90% and a PPV of 70%) and a score < 13 excluded severe SARS-CoV-2 pneumonia (sensitivity > 90% and an NPV of 92%) diagnosed by chest CT scan. 106 

Prognostic implications and utility of LUS scoring Y Lichter et al., found the presence of pleural effusion, pleural thickening, and a high total LUS score at baseline examination were significantly associated with increased mortality. Greater involvement of the anterior segments was a main contributor to the worsening LUS score.

The unadjusted hazard ratio of death for patients with LUS score > 18 was 2.65 [1.14-6.3], p = 0.02, suggesting a 2.6-fold increase in mortality in those patients. 100 Extent of lung involvement on LUS was predictive of the need for intensive care unit admission as noted by Bonadia N et al, patients admitted to ICU had a median 93% of areas involved versus 20% of areas involved in patients who did not require ICU admission. 108 In a study by Zhao L et al., a LUS score cutoff point of more than 32 was found to predict refractory disease (defined as respiratory failure with a PaO2/FiO2 of ≤100 mm Hg or patients who were treated with ECMO) with a specificity of 89.3% and a sensitivity of 57.1%. 109 Description of LUS scores in individual studies is provided in Table S2 . Castelao J et al., used a self-designed scoring system to evaluate severity of lung involvement. The total lung score showed a strong correlation (r = −.765) with the oxygen pressure-to-fraction of inspired oxygen ratio, and the anterior region lung score was significant (OR, 2.159; 95% confidence interval, 1.309-3.561) for the risk of requiring noninvasive respiratory support (NIRS). 98 

Nine studies fulfilled our inclusion criteria. [118] [119] [120] [121] [122] [123] [124] [125] [126] One study included patients in the acute stage and remaining five studies included patients post recovery. 120 Three studies had control groups comparators. 118, 122, 123 Patients underwent MRI because of biochemical evidence of myocardial injury as evidenced by elevated high sensitivity troponin 118, 120 or because of cardiac symptoms 120,121 while other studies performed screening MRI to identify high risk athletes in competitive sports who tested positive for COVID-19 regardless of symptoms. 119, 122, [124] [125] [126] Of note, in one study, none of the patients had elevated cardiac troponins. 119 The study characteristics are fully described in Table 3 

Myocardial edema/late gadolinium enhancement (LGE) and myocarditis pattern Myocardial edema based on T2 sequences was reported in three out of five studies. [119] [120] [121] Lake Louise criteria were satisfied in four out of 26 119 and eight out 10 patients. 120 Similarly, Late gadolinium enhancement (LGE) was reported in five studies. [118] [119] [120] [121] [122] Location and extent of LGE varied between individual studies. Non -ischemic scar was observed in 20 out of 100 patients, 118 in another study, eight patients had scar at RV insertion (two patients), three patchy involvement and three linear involvement. 119 Three out of 10 patients 120 and 14 out of 26 patients 121 had subepicardial LGE, one study reported that most LGE was observed at inferior, and inferolateral basal and mid segments 121 and this was confirmed in other reports. 122 118, 121 One study showed normal T1 values as compared with controls 122 and one study had no comparators. 120 Similarly, native T2 values were elevated compared with controls. 118, 121, 122 Extracellular volume (ECV) was reported in three studies [120] [121] [122] and was significantly elevated compared with controls 122 or patients with negative MRI. 121 Reported values for ECV were ranging between 28 and 36%. 120, 121 One study reported that ECV was increased in midseptum. 122 

Cardiac MRI can have a great clinical implication in assisting in risk stratifying competitive athletes to resume high intensity sports. There has been conflicting data about the true prevalence of myocardial

LGE and/or myocarditis due to COVID-19 sequalae. For instance, in a study of 26 COVID-19 patients, all asymptomatic and with normal EKG and cardiac biomarkers, four patients had evidence of myocarditis on CMR. 119 In another study that involved recovered, previously hospitalized patients with moderate to critical COVID-19, myocarditis was observed in almost 30% on follow up CMR. 123 While in other larger studies, prevalence of abnormalities on CMR was much lower. 124, 125 In a study of 2820 athletes, primary screening with CMR had a lower yield than clinically indicated CMR (referring patients who were identified as high risk on initial screening with EKG/Echo/cardiac biomarkers). Cardiac symptoms and at least one abnormal screening test were the strongest predictors of cardiac involvement on CMR. 124 Also, in another study of 145 asymptomatic or with mild symptoms, the prevalence of myocarditis was only 1.4% on universal screening. 126 While, in another study of 30 patients referred to CMR due to abnormal initial screening, five patients were not allowed to go back to competitive sports due to evidence of myocarditis/or pericarditis. 125 Acute myocarditis as evidenced by myocardial edema and/or LGE can be seen most commonly in the inferior and infero-lateral walls and is usually scattered or sub-epicardial. It seems to be more correlated to cardiac biomarkers as opposed to EKG changes.

In competitive athletes, the role of CMR is yet to be fully understood. CMR evidence of cardiac affection seems to be rare in patients with no symptoms and no abnormal initial screening and it may be reasonable to forego CMR testing before return to high intensity sports in this patient population.

The present review of current literature investigating the various uses of imaging, mainly cardiac, among patients with COVID-19 delineated the wide spectrum of utilization of these imaging modalities in determining the cardiac manifestations among COVID-19 patients and predicting mortality. However, while, the imaging modalities demonstrate a beneficial role among COVID-19 patients, it is imperative to ensure operator safety from acquiring the disease. Further research is needed to evaluate if the routine use of these imaging modalities has any implication on prognostic values and patient outcomes.

None.

Ashish Kumar https://orcid.org/0000-0003-4249-0055

Mariam Shariff https://orcid.org/0000-0001-8799-9678

Medhat Chowdhury https://orcid.org/0000-0003-0008-0496

COVID-19 Map -Johns Hopkins Coronavirus Resource Center

appropriate use criteria for multimodality imaging in the assessment of cardiac structure and function in nonvalvular heart disease: a report of the American College of Cardiology appropriate use criteria

Cardiac manifestations of COVID-19 infection: the role of echocardiography in patient management. Infection. M.Dandel, German Centre for Heart and Circulatory Research (DZHK) Partner Site Berlin

Extrapulmonary manifestations of COVID-19

Acute infection and myocardial infarction

High sensitivity Troponin-T for prediction of adverse events in patients with COVID-19

Usefulness of elevated troponin to predict death in patients with COVID-19 and myocardial injury

Prevalence and prognostic value of elevated troponins in patients hospitalised for coronavirus disease 2019: a systematic review and meta-analysis

Coronavirus and cardiovascular disease, myocardial injury, and arrhythmia: JACC focus seminar

Elevated cardiac troponin i as a predictor of outcomes in covid-19 hospitalizations: a metaanalysis

Elevated N-terminal probrain natriuretic peptide is associated with increased mortality in patients with COVID-19: systematic review and meta-analysis

Indications for and findings on transthoracic echocardiography in COVID-19

Global evaluation of echocardiography in patients with COVID-19

Risk of COVID-19 among frontline healthcare workers and the general community: a prospective cohort study

Impact of COVID-19 pandemic on the role of cardiac sonographers

ASE statement on protection of patients and echocardiography service providers during the 2019 novel coronavirus outbreak: endorsed by the American College of Cardiology

Transthoracic echocardiography during prone position ventilation: lessons from the COVID-19 pandemic

Echocardiography during prone-position mechanical ventilation in patients with COVID-19: a proposal for a new approach

Safety of ultrasonic enhancing agents in patients with COVID-19

Safety with echocardiographic contrast agents

Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort

Contrast echocardiography in VV-ECMO-dependent patients with COVID-19

Ten reasons for performing hemodynamic monitoring using transesophageal echocardiography

Prevalence and prognostic value of acute cor pulmonale and patent foramen ovale in ventilated patients with early acute respiratory distress syndrome: a multicenter study

Comparison of echocardiographic indices used to predict fluid responsiveness in ventilated patients

Predicting preload responsiveness using simultaneous recordings of inferior and superior vena cavae diameters

Two-dimensional assessment of right ventricular function: an echocardiographic-MRI correlative study

Tricuspid annular displacement measured by 2-dimensional speckle tracking echocardiography for predicting right ventricular function in pulmonary hypertension: a new approach to evaluating right ventricle dysfunction. Medicine (Baltimore)

Tricuspid longitudinal annular displacement for the assessment of right ventricular systolic dysfunction during prone positioning in patients with COVID-19

Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry

Use of ECMO in patients with coronavirus disease 2019: does the evidence suffice?

Echocardiography for adult patients supported with extracorporeal membrane oxygenation

The role of echocardiography in the management of patients supported by extracorporeal membrane oxygenation

Critical care transesophageal echocardiography in patients during the COVID-19 pandemic

Echocardiography-guided dual-lumen venovenous extracorporeal membrane oxygenation cannula placement in the ICU-A retrospective review

Echo-guided insertion of a dual-lumen cannula for venovenous extracorporeal membrane oxygenation

Veno-venous extracorporeal membrane oxygenation: cannulation techniques

Critical care ultrasonography during COVID-19 pandemic: the ORACLE protocol

Thrombosis and COVID-19 pneumonia: the clot thickens!

Effect of coronavirus disease 2019 in pulmonary circulation. The particular scenario of precapillary pulmonary hypertension

Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: a different phenotype of thrombotic disease?

Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?

Acute pulmonary hypertension and short-term outcomes in severe covid-19 patients needing intensive care

Biventricular longitudinal strain predict mortality in COVID-19 patients

Acute cor pulmonale in critically ill patients with covid-19

Spectrum of cardiac manifestations in COVID-19: a systematic echocardiographic study

Prognostic utility of quantitative offline 2D-echocardiography in hospitalized patients with COVID-19 disease

Echocardiographic findings in patients with COVID-19 pneumonia

Transthoracic echocardiographic findings in patients admitted with SARS-CoV-2 infection

Acute right ventricular dysfunction in severe COVID-19 pneumonia

Evaluation of biventricular function in patients with COVID-19 using speckle tracking echocardiography

Acute myopericarditis with pericardial effusion and cardiac tamponade in a patient with COVID-19

Echocardiographic characteristics and outcome in patients with COVID-19 infection and underlying cardiovascular disease

Echocardiographic features of COVID-19 illness and association with cardiac biomarkers

Predictive factor for COVID-19 worsening: insights for high-sensitivity troponin and Ddimer and correlation with right ventricular afterload

Comprehensive echocardiographic findings in critically ill COVID-19 patients with or without prior cardiac disease

Left and right ventricular dysfunction in patients with COVID-19-associated myocardial injury

The effect of moderate and severe COVID-19 pneumonia on short-term right ventricular functions: a prospective observational single pandemic center analysis

Usefulness of right ventricular longitudinal shortening fraction to detect right ventricular dysfunction in acute cor pulmonale related to COVID-19

Echocardiographic findings in patients with COVID-19 with significant myocardial injury

Alterations of left ventricular function persisting during post-acute COVID-19 in subjects without previously diagnosed cardiovascular pathology

Left ventricular global longitudinal strain in identifying subclinical myocardial dysfunction among patients hospitalized with COVID-19

Cardiac abnormalities in COVID-19 and relationship to outcome

Characterization of myocardial injury in patients with COVID-19

Subclinical left ventricular dysfunction in COVID-19

Widespread myocardial dysfunction in COVID-19 patients detected by myocardial strain imaging using 2-D speckle-tracking echocardiography

Layer-specific longitudinal strain in Anderson-Fabry disease at diagnosis: a speckle tracking echocardiography analysis

Echocardiographic characteristics of patients with SARS-CoV-2 infection

The different faces of echocardiographic left ventricular hypertrophy: clues to the etiology

Prognostic value of right ventricular ejection fraction assessed by 3D echocardiography in COVID-19 patients

Acute pericarditis and cardiac tamponade in a patient with COVID-19: a therapeutic challenge

Acute myocarditis associated with COVID-19 infection

Systematic review of COVID-19 related myocarditis: insights on management and outcome

Symptomatic pericardial effusion in the setting of asymptomatic COVID-19 infection: a case report

Subacute COVID-19 infection presenting as indolent large pericardial effusion

Acute Effusive pericarditis: a late complication of COVID-19

Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)

Cardiac tamponade secondary to COVID-19

Prognostic value of right ventricular longitudinal strain in patients with COVID-19

Swollen heart in COVID-19 patients who progress to critical illness: a perspective from echo-cardiologists

Biventricular strain by speckle tracking echocardiography in COVID-19: findings and possible prognostic implications

Cardiac tamponade secondary to COVID-19

A pilot study on right ventricular longitudinal strain as a predictor of outcome in COVID-19 patients with evidence of cardiac involvement

Right ventricular-arterial uncoupling independently predicts survival in COVID-19 ARDS

Cardiovascular sequalae in uncomplicated COVID-19 survivors

Evaluation of left ventricular global functions with speckle tracking echocardiography in patients recovered from COVID-19

Relevance of lung ultrasound in the diagnosis of acute respiratory failure: the BLUE protocol

Prospective longitudinal evaluation of point-of-care lung ultrasound in critically ill patients with severe COVID-19 pneumonia

Lung ultrasound in COVID-19 pneumonia: correlations with chest CT on hospital admission. Respiration

Changes in lung ultrasound of symptomatic healthcare professionals with COVID-19 pneumonia and their association with clinical findings

Comparison of chest ultrasound and standard X-Ray imaging in COVID-19 patients

A clinical study of noninvasive assessment of lung lesions in patients with Coronavirus Disease-19 (COVID-19) by bedside ultrasound

Application of lung ultrasonography in critically ill patients with COVID-19

Pointof-care lung ultrasound is more sensitive than chest radiograph for evaluation of COVID-19

Usefulness of lung ultrasound examinations performed by primary care physicians in patients with suspected COVID-19

Is lung ultrasound imaging a worthwhile procedure for severe acute respiratory syndrome coronavirus 2 pneumonia detection?

Lung ultrasound for COVID-19 patchy pneumonia: extended or limited evaluations?

Findings and prognostic value of lung ultrasound in COVID-19 pneumonia

Lung ultrasound in COVID-19 a role beyond the acute phase?

Lung ultrasound predicts clinical course and outcomes in COVID-19 patients

Prospective longitudinal evaluation of point-of-care lung ultrasound in critically ill patients with severe COVID-19 pneumonia

Feasibility of using point-of-care lung ultrasound for early triage of COVID-19 patients in the emergency room

Lung ultrasonography for the diagnosis of SARS-CoV-2 pneumonia in the emergency department

The association of lung ultrasound images with COVID-19 infection in an emergency room cohort

Sensitivity of chest CT for COVID-19: comparison to RT-PCR

Comparative study of lung ultrasound and chest computed tomography scan in the assessment of severity of confirmed COVID-19 pneumonia

Lung ultrasonography in patients with COVID-19: comparison with CT

lung ultrasound findings are associated with mortality and need for intensive care admission in COVID-19 patients evaluated in the emergency department

Lung ultrasound score in evaluating the severity of coronavirus disease 2019 (COVID-19) pneumonia. Ultrasound

Lung ultrasound and respiratory pathophysiology in mechanically ventilated COVID-19 patientsan observational trial

Point-of-care ultrasound in general practice: a systematic review

Point-of-care ultrasound in primary care: a systematic review of generalist performed point-of-care ultrasound in unselected populations

Lung ultrasound score to monitor COVID-19 pneumonia progression in patients with ARDS

How to perform lung ultrasound in pregnant women with suspected COVID-19

Clinical role of lung ultrasound for diagnosis and monitoring of COVID-19 pneumonia in pregnant women

Utility of lung ultrasound assessment for probable SARS-CoV-2 infection during pregnancy and universal screening of asymptomatic individuals

lung ultrasound can influence the clinical treatment of pregnant women with COVID-19

Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)

Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection

Cardiac magnetic resonance characterization of myocarditis-like acute cardiac syndrome in COVID-19

Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging

COVID-19 myocardial pathology evaluated through screening cardiac magnetic resonance (COM-PETE CMR)

Cardiac involvement in COVID-19 patients: mid-term follow up by cardiovascular magnetic resonance

SARS-CoV-2 cardiac involvement in young competitive athletes

Prevalence of inflammatory heart disease among professional athletes with prior COVID-19 infection who received systematic return-to-play cardiac screening

Evaluation for myocarditis in competitive student athletes recovering from coronavirus disease 2019 with cardiac magnetic resonance imaging

Additional supporting information may be found online in the Supporting Information section at the end of the article.